Federal Circuit upholds reverse-payments Cipro deal
The US Court of Appeals for the Federal Circuit has ruled that a $398 million deal between a patent owner and generic pharmaceutical companies does not violate competition law, in the latest controversial case over reverse payments to be decided...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.